ARTICLE | Company News
RFS infectious, cancer, dermatology news
August 15, 2005 7:00 AM UTC
Emory University's Raymond Schinazi will invest $12 million to form RFS. The company has preclinical compounds for cancer, HCV and acne and plans to in-license amdoxovir, a guanosine nucleoside analo...